Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Carcinoma

Carcinoma, Renal Cell

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

All Drugs and Chemicals

Antineoplastic Agents

Amino Acids

Endothelial Growth Factors

Mitogens

Tyrosine Kinase Inhibitors

Lapatinib

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Subjects will receive GW786034 500 milligrams and lapatinib 750 milligrams.

Subjects will receive GW786034 250 milligrams and lapatinib 750 milligrams.

Subjects will receive GW786034 250 milligrams and lapatinib 1000 milligrams.

Subjects will receive GW786034 500 milligrams and lapatinib 1000 milligrams.

Subjects will receive GW786034 250 milligrams and lapatinib 1250 milligrams.

Subjects will receive GW786034 400 milligrams and lapatinib 1250 milligrams.

Subjects will receive GW786034 200 milligrams and lapatinib 1500 milligrams.

Subjects will receive GW786034 400 milligrams and lapatinib 1500 milligrams.

Subjects will receive GW786034 400 milligrams and lapatinib 1000 milligrams.

Subjects will receive GW786034 800 milligrams and lapatinib 1500 milligrams.

GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3, platelet-derived growth factor receptor-alpha (PDGFR-alpha), PDGFR-beta, and c-Kit.

GW786034

Lapatinib is an oral, reversible, tyrosine kinase inhibitor of both epidermal growth factor receptor-1 (ErbB1) and ErbB2.

lapatinib

GSK Clinical Trials

This Phase I, dose finding study evaluates the safety and tolerability of lapatinib, a dual tyrosine kinase inhibitor, and GW786034, an anti-angiogenesis agent, when given together. The study first will find the best doses using safety and blood concentration data of both agents. This is done enrolling stepwise, cohorts of 3 patients each and the last patient enrolled must reach at least Day 22 of continuous daily dosing before the next cohort at an increased dose can begin. If a patient in a cohort has a dose limiting toxicity before Day 22, then 3 more patients are studied at that same dose. If 2 of 6 patients have dose limiting toxicities within the first 22 days, the next cohort receives the next lowest dose. Otherwise each cohort has an increasing dose of one of the two agents. The second stage of the study will administer the best doses of the agents to about 16 patients to further study safety and collect more blood concentration data (more blood samples in the second phase compared to the first phase). The second stage has the advantage of using the best dose (decreases chance of receiving a sub-therapeutic dose) while it collects more blood samples and requires slightly more long clinic visits.

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of Multiple Doses of GW786034 and Lapatinib Concomitantly Administered in Cancer Patients

Spots Global Cancer Trial Database for cancer gw786034 lapatinib pazopanib